Phase 2 Thyroid Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with locally advanced or metastatic differentiated thyroid cancer (including papillary, follicular, oncocytic/Hürthle cell, or poorly differentiated types) that has been confirmed by a tissue biopsy, has stopped responding to radioactive iodine (RAI) treatment, and has grown or spread within the last 12 months, with no prior targeted therapy for this stage of the disease.
• People whose cancer can be measured on scans according to standard criteria (RECIST v1.1).
• People aged 18 or older.
• People who are well enough to carry out basic daily activities, as measured by a standard medical scale (ECOG score of 0, 1, or 2).
• People whose blood counts, liver function, kidney function, and other organ measurements meet the minimum levels required by the trial.
• People living with HIV, provided the infection is well-controlled on stable treatment, with a sufficiently high immune cell count and an undetectable viral load for at least 6 months (confirm specific requirements with the trial site).
• People who have had brain metastases that were previously treated, as long as follow-up scans show no signs of the brain cancer returning and the person has been stable for at least 4 weeks before starting the trial.
• People who can take oral medications by swallowing tablets or receiving them through a feeding tube.
• People who have recovered from side effects of any previous cancer treatments, with only minor or stable residual effects remaining.
• People who are able to understand the trial information and are willing to sign a consent form and follow the trial requirements.
• People who could become pregnant must have a negative pregnancy test before joining.
• People who are sexually active and could father or conceive a child must agree to use highly effective contraception during the trial and for a specified period after the last dose of the study drug, and must agree not to donate eggs or sperm during that time.

Who may not be able to join:

• People who have previously been treated with the study drug XL092 (also called zanzalintinib).
• People who currently have Hepatitis B.
• People who currently have active Hepatitis C (those who have been successfully treated for Hepatitis C and have no detectable virus in the blood may still be considered, confirm with trial site).
• People who are pregnant or currently breastfeeding.
• People who have received any small molecule kinase inhibitor treatment before starting the trial.
• People who have received any other systemic cancer treatment — including chemotherapy, biological therapies, or experimental treatments — before starting the trial.
• People who have had radiation therapy to bone metastases within the past 2 weeks, radiation to any other area within the past 4 weeks, or systemic treatment with radioactive substances within the past 6 weeks before the trial starts.
• People who have a known allergy or sensitivity to the study drug or to similar types of medications.
• People who are taking certain blood-thinning medications (such as warfarin, clopidogrel, or high-dose aspirin), unless specific allowed anticoagulants are being used under conditions outlined by the trial (confirm with trial site).
• People who have used complementary or herbal medicines to treat their cancer within the past 2 weeks.
• People with serious uncontrolled illness or significant ongoing medical conditions that could make participation unsafe.
• People who have had significant bleeding — such as coughing up blood, vomiting blood, or blood in the urine — within the past 12 weeks.
• People with symptomatic cavities or lesions in the lungs that affect the airways.
• People whose cancer has grown into major blood vessels such as the aorta or pulmonary artery.
• People who have had major surgery within the past 8 weeks, keyhole (laparoscopic) surgery within the past 4 weeks, or minor surgery within the past 5 days, or whose surgical wounds have not fully healed.
• People whose heart electrical activity (measured on an ECG) shows a prolonged QT interval above the threshold set by the trial.
• People with a psychiatric condition that could make it difficult to follow the trial requirements or provide informed consent.
• People who have had another active cancer within the past 2 years, or a prior or current cancer that could interfere with assessing the safety or effectiveness of the study treatment (some low-risk skin cancers and certain early-stage prostate cancers may be allowed — confirm with trial site).
• People who have received a live vaccine (such as yellow fever, varicella, or oral polio) within 30 days before starting the trial, or who would need one during the trial.

Important: Always verify eligibility with the trial site directly before applying.